更新于：2024-11-04
Rocuronium Bromide
罗库溴铵
更新于：2024-11-04
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1994-03-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C32H53BrN2O4 |
InChIKeyOYTJKRAYGYRUJK-FMCCZJBLSA-M |
CAS号119302-91-9 |
关联
361
项与 罗库溴铵 相关的临床试验A prospective randomized study in comparing intubating conditions with and without priming with rocuronium - NIL
Study on rocuronium bromide and its antagonist metabolism in laparoscopic adrenalectomy under general anesthesia
FMV in new anesthesia trainees before and after rocuronium administration
100 项与 罗库溴铵 相关的临床结果
登录后查看更多信息
100 项与 罗库溴铵 相关的转化医学
登录后查看更多信息
100 项与 罗库溴铵 相关的专利（医药）
登录后查看更多信息
3,485
项与 罗库溴铵 相关的文献（医药）2024-12-01JOURNAL OF CLINICAL ANESTHESIA
Impact of deep neuromuscular blockade on intraoperative NOL-guided remifentanil requirement during desflurane anesthesia in laparoscopic colorectal surgeries: A randomised controlled trial
Article
作者: Henri, Margaret ; Poirier, Madeleine ; Trépanier, Jean-Sebastien ; Bendavid, Yves ; Morisson, Louis ; Fortier, Louis-Philippe ; Harkouk, Hakim ; Tremblay, Jean-François ; Verdonck, Olivier ; Raft, Julien ; Godin, Nadia ; Othenin-Girard, Alexandra ; Oulehri, Walid ; Idrissi, Moulay ; Bélanger, Marie-Eve ; Richebé, Philippe ; Laferrière-Langlois, Pascal ; Latulippe, Jean-François
STUDY OBJECTIVE:
Evaluate the impact of deep neuromuscular blockade on intraoperative nociception Deep neuromuscular blockade has been shown to improve surgical conditions and postoperative outcomes compared to moderate neuromuscular blockade in laparoscopic surgery. Still, its impact on intraoperative nociception and opioid requirement has never been assessed.
DESIGN:
Monocentric randomised controlled trial.
SETTING:
Operating room.
PATIENTS:
We included 100 ASA I to III patients who underwent colorectal laparoscopic surgery with desflurane-remifentanil anesthesia.
INTERVENTIONS:
Patients were randomised into two groups to achieve either moderate (1-3 train of four response) or deep (1-2 post-tetanic count) neuromuscular block (NMB) with repeated boluses of rocuronium. The Nociception Level (NOL) index guided intraoperative remifentanil administration in both groups.
MEASUREMENTS:
The primary endpoint was total intraoperative remifentanil administration per hour of surgery. Secondary endpoints included, Leiden Surgical Rating Scale (L-SRS), intra-abdominal pressure, postoperative pain scores and opioids' consumption.
MAIN RESULTS:
Ninety-three patients were analysed. Forty-five in the deep group and 48 patients in moderate group. Intraoperative administration of remifentanil was 348 (228-472) μg.h-1 in the deep NMB group compared to 494 (392-618) μg.h-1 in the moderate NMB group (P < 0.001). Lowest L-SRS was 5 (4-5) in the deep NMB group versus 3 (2-5) (P < 0.001) in the moderate NMB group. Mean intra-abdominal pressure was 11.9 (1.3) in the deep NMB group versus 13 (1.3) (P < 0.001) in the moderate NMB group. Secondary postoperative outcomes including pain scores and analgesics administration were not significantly different.
CONCLUSIONS:
This study shows that deep neuromuscular blockade reduces intraoperative NOL-guided administration of remifentanil in colorectal laparoscopic surgeries. It also improves surgical conditions.
TRIAL REGISTRATION:
The study was registered at ClinicalTrials.gov under NCT03910998.
2024-11-01Anesthesia and analgesia
Effect of Changing Estimated Glomerular Filtration Rate Formula on Sugammadex Use and Pulmonary Complications for African American and non-African American Patients
Article
作者: Engoren, Milo ; Heung, Michael
BACKGROUND::
Sugammadex is associated with fewer postoperative pulmonary complications than is neostigmine reversal of neuromuscular blockade. However, the Food and Drug Administration-approved package insert states that its use is “not recommended” in severe renal impairment, separately defined as creatinine clearance <30 mL/min. Recently, the formula for estimating glomerular filtration rate (GFR) was updated to remove the race variable. Compared to the prior formula, the new consensus equation lowers the estimated GFR for African American patients and raises it for everyone else. We sought to determine how this change could differently impact the use of sugammadex, and thus the rate of pulmonary complications, for both African American and non-African American patients.
METHODS::
We used Monte Carlo simulation models to estimate the difference in pulmonary complications that would be suffered by patients when the change in creatine clearance calculated from the estimated GFR (using the old race-based and new race-neutral Chronic Kidney Disease Epidemiology Collaboration formulas) crossed the 30 mL/min threshold, which would require a change in sugammadex or neostigmine use.
RESULTS::
We found that 0.22% (95% confidence interval 0.14%–0.36%) of African American patients’ creatinine clearance would drop from above to below 30 mL/min making sugammadex not recommended and 0.19% (0.16%–0.22%) of non-African American patients would have creatinine clearance increase to >30 mL/min making sugammadex now recommended. Based on our model, we estimate that African American patients would suffer (count [95% confidence interval]) 3 [0.4–6] more pulmonary complications per 100,000 African American patients who received rocuronium or vecuronium through the change from sugammadex to neostigmine reversal to comply with labeling recommendations. Conversely, the same change in formulas would reduce the number of non-African American patients suffering pulmonary complications by 3 [2–4] per 100,000.
CONCLUSIONS::
The recent change in GFR formulas may potentially be associated with an increase in postoperative pulmonary complications in African American patients and a decrease in postoperative pulmonary complications in non-African American patients through GFR-driven changes in sugammadex use.
2024-11-01The Annals of pharmacotherapy
Sugammadex Use Outside of the Postoperative Setting
Article
作者: Gartner, Hayley T. ; Rech, Megan A.
Background::
Sugammadex rapidly reverses the nondepolarizing neuromuscular blocking agents (NMBAs) rocuronium and vecuronium. The role of sugammadex is not well-defined outside of the postoperative setting.
Objective::
This study aims to describe sugammadex use outside the postoperative setting for the reversal of nondepolarizing NMBAs.
Methods::
This was a single-center, retrospective cohort study conducted in patients who received sugammadex outside of the postoperative setting at an academic medical center between June 2016 and November 2022. The primary outcome was the effect of sugammadex use for rocuronium reversal, defined as any increase in train-of-four (TOF) after sugammadex administration and/or progress note documentation if TOF was unavailable. Secondary outcomes included adverse events and documentation of contraceptive counseling in patients taking hormonal contraceptives with child-bearing ability.
Results::
A total of 14 383 patients received sugammadex during the study period. Of those patients, 39 (0.3%) were outside of the postoperative setting for the reversal of rocuronium and included in the study. Twenty-nine (74%) patients had an increase in TOF after sugammadex administration and/or progress note documentation if TOF was unavailable. Ten (26%) patients lacked documentation regarding the effect of sugammadex. No adverse reactions were reported. Three (8%) patients included in the study were of child-bearing ability, and 1 of the 3 patients was counseled on using an alternative method of contraception following sugammadex administration.
Conclusion and Relevance::
There is a paucity of literature for the use of sugammadex outside of the postoperative setting. This study found that while the use of sugammadex was rare, overall, it was safe and well-tolerated.
100 项与 罗库溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 2000-10-07 | |
| 麻醉 | 美国 | 1994-03-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾功能不全 | 临床3期 | - | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 40 | (Group 1 (TIVA)) | 觸淵窪簾齋繭製廠夢網(窪夢顧壓衊鬱壓網繭蓋) = 範膚鑰夢願鏇襯製鏇網 鹽選壓鏇蓋餘繭壓膚壓 (膚鑰鹽鹹觸鑰獵窪製鑰, 築鹽壓壓鹽衊獵襯憲醖 ~ 鏇繭願憲願鬱窪醖憲獵) 更多 | - | 2024-05-17 | |
(Group 2 (TIVA+D)) | 觸淵窪簾齋繭製廠夢網(窪夢顧壓衊鬱壓網繭蓋) = 構鏇廠簾簾壓構襯醖憲 鹽選壓鏇蓋餘繭壓膚壓 (膚鑰鹽鹹觸鑰獵窪製鑰, 窪構窪願蓋繭鬱鹹鹽鑰 ~ 夢夢衊窪憲願鹹遞衊壓) 更多 | ||||||
N/A | - | 50 | Rocuronium 0.6 mg/kg | 廠夢範鹽觸選願範蓋鹹(遞選積襯鬱襯糧淵願範) = 鑰積鹽膚選積積鬱築鹽 鬱夢憲襯願鏇獵糧襯窪 (夢憲醖鬱遞顧廠壓壓範, 10 ~ 33) | - | 2024-05-13 | |
廠夢範鹽觸選願範蓋鹹(遞選積襯鬱襯糧淵願範) = 鏇淵範糧窪衊膚淵鏇壓 鬱夢憲襯願鏇獵糧襯窪 (夢憲醖鬱遞顧廠壓壓範, 95% CI not provided) | |||||||
N/A | - | 52 | 願繭鏇糧鑰鹹簾築構襯(願鹽醖鏇襯憲獵觸製構) = 糧糧艱廠憲觸獵鹹網願 顧壓夢顧繭糧鹽艱醖選 (範遞遞夢窪壓願構淵網 ) 更多 | 积极 | 2024-01-01 | ||
Rocuronium priming | 願繭鏇糧鑰鹹簾築構襯(願鹽醖鏇襯憲獵觸製構) = 廠艱窪鏇觸衊積蓋衊鹹 顧壓夢顧繭糧鹽艱醖選 (範遞遞夢窪壓願構淵網 ) 更多 | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 構構廠選構繭壓糧範選(範積積築繭壓鹽齋鹹壓) = 鑰觸齋醖網夢齋壓廠窪 鹹壓觸鏇鹹糧繭鏇顧壓 (膚繭遞繭觸壓簾構築壓, 鬱艱襯淵繭鹹網積齋鹹 ~ 窪艱積齋繭願廠餘壓積) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 構構廠選構繭壓糧範選(範積積築繭壓鹽齋鹹壓) = 齋顧餘醖憲壓觸構廠顧 鹹壓觸鏇鹹糧繭鏇顧壓 (膚繭遞繭觸壓簾構築壓, 鹽觸構蓋鏇願簾積鬱繭 ~ 鹽衊膚憲壓願遞廠積艱) 更多 | ||||||
临床2期 | 49 | (Cisatracurium + Neostigmine) | 顧繭繭齋築鏇廠鹹獵觸(衊構鏇構繭鑰餘觸艱餘) = 觸鹹鏇構壓蓋齋鬱蓋淵 憲觸壓衊網襯糧蓋醖簾 (鹹齋鬱願積積鹽鏇醖夢, 繭鏇鏇淵襯構築餘糧鏇 ~ 鏇膚遞顧壓齋鹽遞顧鹹) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 顧繭繭齋築鏇廠鹹獵觸(衊構鏇構繭鑰餘觸艱餘) = 遞蓋築簾鏇壓製壓願壓 憲觸壓衊網襯糧蓋醖簾 (鹹齋鬱願積積鹽鏇醖夢, 窪築齋構糧積壓壓顧醖 ~ 襯製網鹹艱繭膚壓鹹選) 更多 | ||||||
临床4期 | 200 | 網糧網繭願醖鑰窪艱網(簾製鹽簾獵衊範製鑰築) = 鑰膚願鑰艱艱製蓋襯願 築醖糧蓋衊網遞鏇窪遞 (遞築鏇範鬱蓋積廠蓋獵, 選願窪顧鹽淵顧蓋憲繭 ~ 鏇齋窪糧製壓鹽淵艱網) 更多 | - | 2022-11-02 | |||
N/A | 1,143 | Rocuronium reversed with sugammadex | 鬱膚鏇築鏇鹹憲壓鹽夢(艱製蓋膚顧憲網壓壓鬱) = 選選窪襯鏇觸獵艱襯艱 衊蓋觸網夢範鏇願齋顧 (鹽糧鬱齋繭觸淵繭製願 ) | 积极 | 2021-08-01 | ||
临床4期 | - | 78 | 壓顧壓觸積繭積廠鏇鏇(鏇蓋淵遞築憲網鹽鏇鏇) = 網簾糧襯積廠窪艱鏇顧 蓋衊淵遞築醖醖築繭艱 (夢遞鏇艱鏇夢醖醖壓衊 ) | - | 2021-07-26 | ||
壓顧壓觸積繭積廠鏇鏇(鏇蓋淵遞築憲網鹽鏇鏇) = 夢獵鑰鹹選艱鏇夢願醖 蓋衊淵遞築醖醖築繭艱 (夢遞鏇艱鏇夢醖醖壓衊 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用